» Articles » PMID: 38469086

Long Term Follow-up in GAMT Deficiency - Correlation of Therapy Regimen, Biochemical and Brain Proton MR Spectroscopy Data

Overview
Specialty Endocrinology
Date 2024 Mar 12
PMID 38469086
Authors
Affiliations
Soon will be listed here.
Abstract

GAMT deficiency is a rare autosomal recessive disease within the group of cerebral creatine deficiency syndromes. Cerebral creatine depletion and accumulation of guanidinoacetate (GAA) lead to clinical presentation with intellectual disability, seizures, speech disturbances and movement disorders. Treatment consists of daily creatine supplementation to increase cerebral creatine, reduction of arginine intake and supplementation of ornithine for reduction of toxic GAA levels. This study represents the first long-term follow-up over a period of 14 years, with detailed clinical data, biochemical and multimodal neuroimaging findings. Developmental milestones, brain MRI, quantitative single voxel H magnetic resonance spectroscopy (MRS) and biochemical analyses were assessed. The results reveal insights into the dose dependent effects of creatine/ornithine supplementation and expand the phenotypic spectrum of GAMT deficiency. Of note, the creatine concentrations, which were regularly monitored over a long follow-up period, increased significantly over time, but did not reach age matched control ranges. Our patient is the second reported to show normal neurocognitive outcome after an initial delay, stressing the importance of early diagnosis and treatment initiation.

Citing Articles

Establishing a Core Outcome Set for Creatine Transporter Deficiency and Guanidinoacetate Methyltransferase Deficiency.

Nasseri Moghaddam Z, Reinhardt E, Thurm A, Potter B, Smith M, Graham C medRxiv. 2024; .

PMID: 39371127 PMC: 11451665. DOI: 10.1101/2024.09.06.24313213.

References
1.
Hanna-El-Daher L, Braissant O . Creatine synthesis and exchanges between brain cells: What can be learned from human creatine deficiencies and various experimental models?. Amino Acids. 2016; 48(8):1877-95. DOI: 10.1007/s00726-016-2189-0. View

2.
Almeida L, Verhoeven N, Roos B, Valongo C, Cardoso M, Vilarinho L . Creatine and guanidinoacetate: diagnostic markers for inborn errors in creatine biosynthesis and transport. Mol Genet Metab. 2004; 82(3):214-9. DOI: 10.1016/j.ymgme.2004.05.001. View

3.
Frahm J, Bruhn H, Gyngell M, Merboldt K, Hanicke W, Sauter R . Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med. 1989; 9(1):79-93. DOI: 10.1002/mrm.1910090110. View

4.
Wojcik M, Morrissey M, Borden K, Teta B, Sicko R, Showers A . Method modification to reduce false positives for newborn screening of guanidinoacetate methyltransferase deficiency. Mol Genet Metab. 2022; 135(3):186-192. DOI: 10.1016/j.ymgme.2022.01.101. View

5.
Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, Appleton R, Araujo H, Duran M . GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. Neurology. 2006; 67(3):480-4. DOI: 10.1212/01.wnl.0000234852.43688.bf. View